Updated: Merck, without sharing details, says RSV antibody successfully protected infants
Merck’s monoclonal antibody to protect infants from RSV hit its goals in a Phase 2b/3 trial, putting the US drugmaker a step closer to competing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
